This Week in Oncology — Jul 1, 2026

Editor's Pick: SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial (The Lancet. Oncology, 2026)
Welcome to This Week in Oncology. This week we are covering ten notable papers spanning breast cancer treatment optimization, the limits of local treatment intensification, and emerging combined-modality therapies for advanced malignancies. Let us dive in.
This week's papers:
• Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372745)
• Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372741)
• Dose escalation with intraoperative radiotherapy in newly diagnosed glioblastoma (INTRAGO-II): an open-label, multicentre, randomised, controlled, phase 3 trial — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372746)
• Internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer (EORTC trial 22922/10925): an unplanned subset analysis of 20-year outcomes in patients with node-negative breast cancer — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372743)
• Tailoring radiotherapy in cT1-2N1 breast cancer to nodal response on primary chemotherapy (RAPCHEM: BOOG 2010-03): 10-year follow-up results of a Dutch, prospective, registry study — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372742)
• SBRT plus abiraterone acetate and ADT versus abiraterone acetate and ADT in oligometastatic castrate-resistant prostate cancer (ARTO): long-term, unplanned overall survival analysis of an open-label, randomised, phase 2 trial — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372744)
• Reirradiation for recurrent head and neck squamous cell carcinoma: international expert consensus recommendations endorsed by the Reirradiation Collaborative Group, the European Society for Radiotherapy and Oncology Reirradiation Focus Group, and the American Society for Radiation Oncology — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372755)
• European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine — The Lancet. Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42372754)
• Claudin 18.2 Targeting: A Pan-Cancer Perspective — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42378036)
Listen at AudioScholar (audioscholar.cc/episode/j7kxhsexvv)